{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:26:22Z","timestamp":1783045582407,"version":"3.54.6"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The purpose of this study was to evaluate the incidence of acute genitourinary toxicities in patients undergoing pencil beam scanning proton therapy for prostate cancer and investigate predictive factors associated with acute urinary retention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 227 patients treated between 2018 and 2021 were divided into the normo-fractionated proton therapy group (n\u00a0=\u00a0107) and the moderately hypo-fractionated proton therapy group (n\u00a0=\u00a0120), with prescribed doses of 76\u201378\u00a0Gy relative biological effectiveness in 38\u201339 fractions and 60\u201363\u00a0Gy relative biological effectiveness in 20\u201321 fractions, respectively. Uroflowmetry parameters and the transition zone index were prospectively evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-five patients (42%) in the normo-fractionated proton therapy and 33 (28%) in the moderately hypo-fractionated proton therapy developed acute grade 2 genitourinary toxicities (P\u00a0=\u00a00.02). The most common acute genitourinary toxicity was acute urinary retention. Thirty-nine patients (36%) treated with normo-fractionated proton therapy and 27 (23%) treated with moderately hypo-fractionated proton therapy developed grade 2 acute urinary retention (P\u00a0=\u00a00.02). No patients developed grade\u00a0\u2265\u00a03 toxicity. Univariate analysis showed the transition zone index, prostate volume, international prostate symptom score, voided volume, maximum flow rate and average flow rate were associated with grade 2 acute urinary retention. Multivariate analysis in both groups revealed the transition zone index (P\u00a0=\u00a00.025 and 0.029) and average flow rate (P\u00a0=\u00a00.039 and 0.044) were predictors of grade 2 acute urinary retention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The incidence of acute genitourinary toxicities was lower in the moderately hypo-fractionated proton therapy compared with the normo-fractionated proton therapy. Lower pretreatment average flow rate and a higher transition zone index were useful predictors of grade 2 acute urinary retention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad005","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:22:02Z","timestamp":1675286522000},"page":"419-428","source":"Crossref","is-referenced-by-count":8,"title":["Acute genitourinary toxicity of pencil beam scanning proton therapy for localized prostate cancer: utility of the transition zone index and average urinary flow rate in predicting acute urinary retention"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-8923","authenticated-orcid":false,"given":"Taiki","family":"Takaoka","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Narita Memorial Proton Center , Toyohashi , Japan"},{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Narita Memorial Proton Center , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Narita Memorial Hospital , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kiriyama","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Narita Memorial Hospital , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Radiology, Narita Memorial Hospital , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhito","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Narita Memorial Proton Center , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Shibamoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Narita Memorial Proton Center , Toyohashi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Hiwatashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"2023050106130466800_ref1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jrr\/rrt124","article-title":"Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer","volume":"55","author":"Manabe","year":"2014","journal-title":"J Radiat Res"},{"key":"2023050106130466800_ref2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajco.13097","article-title":"Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer","volume":"15","author":"Tomita","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"2023050106130466800_ref3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jrr\/rry089","article-title":"Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer","volume":"60","author":"Takemoto","year":"2019","journal-title":"J Radiat Res"},{"key":"2023050106130466800_ref4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jjco\/hyab167","article-title":"Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study","volume":"52","author":"Sasamura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106130466800_ref5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jrr\/rrac027","article-title":"Comparison of intensity-modulated radiotherapy with the 5-field technique, helical tomotherapy and volumetric modulated arc therapy for localized prostate cancer","volume":"63","author":"Kita","year":"2022","journal-title":"J Radiat Res"},{"key":"2023050106130466800_ref6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0360-3016(99)00232-1","article-title":"Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer","volume":"45","author":"Zelefsky","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref7","doi-asserted-by":"crossref","first-page":"1533033820985866","DOI":"10.1177\/1533033820985866","article-title":"Dosimetric comparison of helical tomotherapy, volumetric-modulated arc therapy, and intensity-modulated proton therapy for angiosarcoma of the scalp","volume":"20","author":"Mizuno","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"2023050106130466800_ref8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14338\/IJPT-D-20-00043.1","article-title":"Spot scanning proton therapy for sinonasal malignant tumors","volume":"8","author":"Nakajima","year":"2021","journal-title":"Int J Part Ther"},{"key":"2023050106130466800_ref9","doi-asserted-by":"crossref","first-page":"15330338211060170","DOI":"10.1177\/15330338211060170","article-title":"Dosimetric comparison of helical tomotherapy and intensity-modulated proton therapy in hippocampus- and scalp-sparing whole brain radiotherapy","volume":"20","author":"Takaoka","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"2023050106130466800_ref10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0090-4295(97)00685-7","article-title":"Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia","volume":"51","author":"Kurita","year":"1998","journal-title":"Urology"},{"key":"2023050106130466800_ref11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jmri.25418","article-title":"MRI evaluation of benign prostatic hyperplasia: correlation with international prostate symptom score","volume":"45","author":"Guneyli","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"2023050106130466800_ref12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jjco\/hyaa172","article-title":"Feasibility of transrectal and transperineal fiducial marker placement for prostate cancer before proton therapy","volume":"51","author":"Ohta","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106130466800_ref13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jjco\/hyz171","article-title":"Efficacy of a hydrogel spacer in three-dimensional conformal radiation therapy for prostate cancer","volume":"50","author":"Ogita","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106130466800_ref15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jrr\/rrab002","article-title":"Changes in sexual function and serum testosterone levels in patients with prostate cancer after image-guided proton therapy","volume":"62","author":"Hattori","year":"2021","journal-title":"J Radiat Res"},{"key":"2023050106130466800_ref16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/cancers14030517","article-title":"Patient-reported quality of life outcomes after moderately hypofractionated and normofractionated proton therapy for localized prostate cancer","volume":"14","author":"Nakajima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023050106130466800_ref17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","article-title":"Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer","volume":"79","author":"Arcangeli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.adro.2017.12.006","article-title":"Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer","volume":"3","author":"Wang","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"2023050106130466800_ref19","first-page":"637","article-title":"International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer","volume":"77","author":"Tomita","year":"2015","journal-title":"Nagoya J Med Sci"},{"key":"2023050106130466800_ref20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1748-717X-9-163","article-title":"Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer","volume":"9","author":"Arscott","year":"2014","journal-title":"Radiat Oncol"},{"key":"2023050106130466800_ref21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jjco\/hyab094","article-title":"Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities","volume":"51","author":"Ito","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106130466800_ref22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijrobp.2007.03.009","article-title":"Acute morbidity of proton therapy for prostate cancer: the Hyogo ion beam medical Center experience","volume":"69","author":"Mayahara","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2010.05.027","article-title":"Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities","volume":"81","author":"Nihei","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10147-017-1209-8","article-title":"Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer","volume":"23","author":"Nakajima","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2023050106130466800_ref25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jmrs.551","article-title":"Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer","volume":"69","author":"Iizumi","year":"2022","journal-title":"J Med Radiat Sci"},{"key":"2023050106130466800_ref26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2019.05.069","article-title":"Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer","volume":"105","author":"Grewal","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ctro.2019.08.006","article-title":"Proton beam therapy delivered using pencil beam scanning vs. passive scattering\/uniform scanning for localized prostate cancer: comparative toxicity analysis of PCG 001-09","volume":"19","author":"Mishra","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"2023050106130466800_ref28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/0284186X.2013.764011","article-title":"A phase II study of hypofractionated proton therapy for prostate cancer","volume":"52","author":"Kim","year":"2013","journal-title":"Acta Oncol"},{"key":"2023050106130466800_ref29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2016.02.025","article-title":"Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study \u2013 the IPI trial","volume":"95","author":"Habl","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref30","doi-asserted-by":"crossref","first-page":"808216","DOI":"10.3389\/fonc.2021.808216","article-title":"Two-year toxicity and efficacy of carbon ion radiotherapy in the treatment of localized prostate cancer: a single-centered study","volume":"11","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"2023050106130466800_ref31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-020-01575-7","article-title":"Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer","volume":"15","author":"Takakusagi","year":"2020","journal-title":"Radiat Oncol"},{"key":"2023050106130466800_ref32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2009.12.053","article-title":"Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy","volume":"79","author":"King","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijrobp.2010.01.022","article-title":"Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate","volume":"80","author":"Roeloffzen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106130466800_ref34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0022-5347(01)66779-X","article-title":"Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure","volume":"154","author":"Kaplan","year":"1995","journal-title":"J Urol"},{"key":"2023050106130466800_ref35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/luts.12431","article-title":"The cutoff value of transitional zone index predicting the efficacy of dutasteride on subjective symptoms in patients with benign prostate hyperplasia","volume":"14","author":"Kamei","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"2023050106130466800_ref36","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00345-020-03398-3","article-title":"A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study","volume":"39","author":"Tsirkas","year":"2021","journal-title":"World J Urol"},{"key":"2023050106130466800_ref37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2004.09.036","article-title":"Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study","volume":"62","author":"Elshaikh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/5\/419\/50138024\/hyad005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/5\/419\/50138024\/hyad005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T06:13:35Z","timestamp":1682921615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/5\/419\/7017409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,31]]},"published-print":{"date-parts":[[2023,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad005","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,1,31]]}}}